Hackett Gretchen, Aziz Faisal, Samii Soraya, Imundo Jason R
Division of Pediatric Cardiology, Penn State Health Children's Hospital, Hershey, PA, USA.
Division of Vascular Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
J Innov Card Rhythm Manag. 2021 Apr 15;12(4):4482-4486. doi: 10.19102/icrm.2021.120403. eCollection 2021 Apr.
The Micra™ transcatheter pacing system (TPS) (Medtronic, Minneapolis, MN, USA) is the only leadless pacemaker currently approved by the United States Food and Drug Administration. A limitation to the use of this device in the pediatric population is the large size of the delivery sheath. We present a 28-kg, nine-year-old male with symptomatic asystolic pauses who underwent successful placement of a Micra™ TPS via right internal jugular vein surgical cutdown as a first-line option. Current reports in the literature using the right internal jugular vein due to small patient size are limited to those involving patients with concurrent medical conditions that render the use of traditional systems unfavorable or contraindicated. Given the potential benefits of a leadless pacemaker system, its use in the pediatric population will likely continue to increase with time. This case describes technical strategies and procedural caveats that could aid in continued successful implantations of the Micra™ TPS in smaller patients as first-line therapy. In this report, room setup, the use of preprocedure vascular duplex studies, sheath manipulation, and a multidisciplinary approach are reviewed.
Micra™ 经导管起搏系统(TPS)(美敦力公司,美国明尼阿波利斯市)是目前唯一获得美国食品药品监督管理局批准的无导线起搏器。该设备在儿科人群中使用的一个限制因素是输送鞘管尺寸较大。我们报告一例体重28千克、9岁的男性患者,有症状性心搏停止间歇,作为一线选择,通过右颈内静脉手术切开成功植入了Micra™ TPS。目前文献中因患者体型小而使用右颈内静脉的报告仅限于那些同时患有使传统系统使用不利或禁忌的疾病的患者。鉴于无导线起搏器系统的潜在益处,随着时间的推移,其在儿科人群中的使用可能会继续增加。本病例描述了有助于在较小患者中继续成功将Micra™ TPS作为一线治疗进行植入的技术策略和操作注意事项。在本报告中,对房间设置、术前血管超声检查的使用、鞘管操作以及多学科方法进行了综述。